Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
Crossref DOI link: https://doi.org/10.1007/s40273-015-0307-6
Published Online: 2015-06-21
Published Print: 2015-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Svensson, Mikael
Nilsson, Fredrik O. L.
Arnberg, Karl
Funding for this research was provided by:
Swedish Research Council for Health, Working Life and Welfare
Text and Data Mining valid from 2015-06-21